Treatment options for the management of diabetic painful neuropathy: best current evidence.
(1) A large number of treatment options have shown generally moderate efficacy in the treatment of diabetic painful neuropathy.(2) Tricyclic antidepressants are the mainstay of therapy, with anticonvulsants, opioids and serotonin-noradrenaline reuptake inhibitors also having a place.(3) Head-to-head trials of current treatments are needed. Meanwhile, selection of therapeutic agents should be individualised.
McKeage
Kate
K
Wolters Kluwer Health | Adis, Auckland, New Zealand.
D000700:Analgesics / Q000494:pharmacology / Q000592:standards*; D000701:Analgesics, Opioid / Q000494:pharmacology / Q000592:standards; D000927:Anticonvulsants / Q000494:pharmacology / Q000592:standards; D000929:Antidepressive Agents, Tricyclic / Q000494:pharmacology / Q000592:standards; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data*; D003929:Diabetic Neuropathies / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology / Q000592:standards; D016896:Treatment Outcome
D000700:Analgesics; D000701:Analgesics, Opioid; D000927:Anticonvulsants; D000929:Antidepressive Agents, Tricyclic; D017367:Selective Serotonin Reuptake Inhibitors